echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > AP&T: The relationship between central obesity and hepatocellular carcinoma in patients with chronic hepatitis B antiviral therapy

    AP&T: The relationship between central obesity and hepatocellular carcinoma in patients with chronic hepatitis B antiviral therapy

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hepatocellular carcinoma (HCC) is the main cause of death in patients with chronic hepatitis B (CHB).


    Hepatocellular carcinoma (HCC) is the main cause of death in patients with chronic hepatitis B (CHB).


     


     


    Figure: The relationship between obesity and hepatocellular carcinoma



     

    Original source:

    Rong Fan.


    Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.